MedPath

Alopexx Oncology, LLC

Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (100.0%)

Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL

Phase 1
Terminated
Conditions
B-cell Non-Hodgkin Lymphoma
Interventions
First Posted Date
2014-06-02
Last Posted Date
2020-11-27
Lead Sponsor
Alopexx Oncology, LLC
Target Recruit Count
5
Registration Number
NCT02151903
Locations
🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

🇺🇸

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL

Phase 1
Terminated
Conditions
B-cell Non-Hodgkin Lymphoma
Interventions
First Posted Date
2013-06-11
Last Posted Date
2020-11-24
Lead Sponsor
Alopexx Oncology, LLC
Target Recruit Count
24
Registration Number
NCT01874288
Locations
🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

St. Jude Hospital Yorba Linda, Fullerton, California, United States

🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

and more 2 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.